NO331448B1 - Oral vandig opplosning av 4-amino-5-klor-2,3-dihydro-N-[1-(3-metoksypropyl)-4-pipeidinyl]-7-benzenfuran-karboksamid (prucaloprid) og fremgangsmate for fremstilling derav - Google Patents

Oral vandig opplosning av 4-amino-5-klor-2,3-dihydro-N-[1-(3-metoksypropyl)-4-pipeidinyl]-7-benzenfuran-karboksamid (prucaloprid) og fremgangsmate for fremstilling derav Download PDF

Info

Publication number: NO331448B1
Authority: NO; Norway
Prior art keywords: prucalopride; acid; oral; addition salt; methoxypropyl
Prior art date: 1999-04-29

Application number

NO20014794A

Other languages

English (en)

Norwegian (no)

Other versions

NO20014794D0 (no

NO20014794L (no

Inventor

Eddy Andre Josee De Proost

Original Assignee

Shire Movetis Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-29

Filing date

2001-10-02

Publication date

2012-01-02

2001-10-02 Application filed by Shire Movetis Nv filed Critical Shire Movetis Nv

2001-10-02 Publication of NO20014794D0 publication Critical patent/NO20014794D0/no

2001-10-02 Publication of NO20014794L publication Critical patent/NO20014794L/no

2012-01-02 Publication of NO331448B1 publication Critical patent/NO331448B1/no

Links

ZPMNHBXQOOVQJL-UHFFFAOYSA-N prucalopride Chemical compound C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 ZPMNHBXQOOVQJL-UHFFFAOYSA-N 0.000 title claims abstract description 23
229960003863 prucalopride Drugs 0.000 title claims abstract description 23
239000007864 aqueous solution Substances 0.000 title claims abstract description 7
238000002360 preparation method Methods 0.000 title claims description 10
238000000034 method Methods 0.000 title claims description 5
-1 3-methoxypropyl Chemical group 0.000 title description 3
150000003839 salts Chemical class 0.000 claims abstract description 17
239000002253 acid Substances 0.000 claims abstract description 13
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 18
229940100688 oral solution Drugs 0.000 claims description 11
235000010233 benzoic acid Nutrition 0.000 claims description 10
239000000243 solution Substances 0.000 claims description 10
239000005711 Benzoic acid Substances 0.000 claims description 9
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 9
235000003599 food sweetener Nutrition 0.000 claims description 8
239000003765 sweetening agent Substances 0.000 claims description 8
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
239000000600 sorbitol Substances 0.000 claims description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
235000013615 non-nutritive sweetener Nutrition 0.000 claims description 4
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical group C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000000203 mixture Substances 0.000 description 10
230000035807 sensation Effects 0.000 description 10
235000019615 sensations Nutrition 0.000 description 10
238000009472 formulation Methods 0.000 description 8
230000008447 perception Effects 0.000 description 7
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000000796 flavoring agent Substances 0.000 description 6
235000019634 flavors Nutrition 0.000 description 6
239000003755 preservative agent Substances 0.000 description 6
241000220223 Fragaria Species 0.000 description 4
235000016623 Fragaria vesca Nutrition 0.000 description 4
235000011363 Fragaria x ananassa Nutrition 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000000694 effects Effects 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
239000007958 cherry flavor Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000008213 purified water Substances 0.000 description 3
239000001384 succinic acid Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
NNOYLBKZPCUCQT-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-3-olate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 NNOYLBKZPCUCQT-UHFFFAOYSA-L 0.000 description 2
235000013736 caramel Nutrition 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000001129 nonadrenergic effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
108091005477 5-HT3 receptors Proteins 0.000 description 1
102000035037 5-HT3 receptors Human genes 0.000 description 1
108091005482 5-HT4 receptors Proteins 0.000 description 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
208000010470 Ageusia Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
101150104779 HTR2A gene Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108050004114 Monellin Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
240000001890 Ribes hudsonianum Species 0.000 description 1
235000016954 Ribes hudsonianum Nutrition 0.000 description 1
235000001466 Ribes nigrum Nutrition 0.000 description 1
240000007651 Rubus glaucus Species 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
239000004376 Sucralose Substances 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
235000010358 acesulfame potassium Nutrition 0.000 description 1
229960004998 acesulfame potassium Drugs 0.000 description 1
239000000619 acesulfame-K Substances 0.000 description 1
235000019666 ageusia Nutrition 0.000 description 1
239000000556 agonist Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
150000001559 benzoic acids Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
239000008370 chocolate flavor Substances 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
230000013872 defecation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000009826 distribution Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
230000009540 excitatory neurotransmission Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000008369 fruit flavor Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
239000000905 isomalt Substances 0.000 description 1
235000010439 isomalt Nutrition 0.000 description 1
HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000008368 mint flavor Substances 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000002536 noncholinergic effect Effects 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940116315 oxalic acid Drugs 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
229960001462 sodium cyclamate Drugs 0.000 description 1
AYGJDUHQRFKLBG-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;dihydrate Chemical compound O.O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 AYGJDUHQRFKLBG-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
229940013618 stevioside Drugs 0.000 description 1
OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
235000019202 steviosides Nutrition 0.000 description 1
235000019408 sucralose Nutrition 0.000 description 1
BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

NO20014794A 1999-04-29 2001-10-02 Oral vandig opplosning av 4-amino-5-klor-2,3-dihydro-N-[1-(3-metoksypropyl)-4-pipeidinyl]-7-benzenfuran-karboksamid (prucaloprid) og fremgangsmate for fremstilling derav NO331448B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99201335		1999-04-29
PCT/EP2000/003739 WO2000066170A1 (en)	1999-04-29	2000-04-20	Prucalopride oral solution

Publications (3)

Publication Number	Publication Date
NO20014794D0 NO20014794D0 (no)	2001-10-02
NO20014794L NO20014794L (no)	2001-10-02
NO331448B1 true NO331448B1 (no)	2012-01-02

Family

ID=8240160

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20014794A NO331448B1 (no)	1999-04-29	2001-10-02	Oral vandig opplosning av 4-amino-5-klor-2,3-dihydro-N-[1-(3-metoksypropyl)-4-pipeidinyl]-7-benzenfuran-karboksamid (prucaloprid) og fremgangsmate for fremstilling derav

Country Status (36)

Country	Link
US (1)	US6413988B1 (de)
EP (1)	EP1176982B1 (de)
JP (1)	JP4773619B2 (de)
KR (1)	KR100669175B1 (de)
CN (1)	CN1165345C (de)
AR (1)	AR023815A1 (de)
AT (1)	ATE254929T1 (de)
AU (1)	AU770073B2 (de)
BG (1)	BG65061B1 (de)
BR (1)	BRPI0010150B8 (de)
CA (1)	CA2371178C (de)
CZ (1)	CZ294070B6 (de)
DE (1)	DE60006799T2 (de)
DK (1)	DK1176982T3 (de)
EA (1)	EA003904B1 (de)
EE (1)	EE05264B1 (de)
ES (1)	ES2211546T3 (de)
HK (1)	HK1045950B (de)
HR (1)	HRP20010764B1 (de)
HU (1)	HU228924B1 (de)
ID (1)	ID30397A (de)
IL (2)	IL146152A0 (de)
JO (1)	JO2181B1 (de)
MX (1)	MXPA01010953A (de)
MY (1)	MY119880A (de)
NO (1)	NO331448B1 (de)
NZ (1)	NZ515119A (de)
PL (1)	PL195674B1 (de)
PT (1)	PT1176982E (de)
SI (1)	SI1176982T1 (de)
SK (1)	SK284847B6 (de)
TR (1)	TR200103121T2 (de)
TW (1)	TW592709B (de)
UA (1)	UA68426C2 (de)
WO (1)	WO2000066170A1 (de)
ZA (1)	ZA200108820B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050063998A1 (en) *	1999-10-26	2005-03-24	Francois Marc Karel Jozef	Oral solution containing galantamine and a sweetening agent
AU2002231627A1 (en) *	2000-11-24	2002-06-03	Janssen Pharmaceutica N.V.	Use of a triple combination comprising a 5HT3 antagonist, a 5HT4 agonist and a laxative for promoting intestinal lavage
RU2301806C2 (ru) *	2002-01-16	2007-06-27	Янссен Фармацевтика Н.В.	Прукалоприд-n-оксид
JP4526247B2 (ja) *	2002-07-08	2010-08-18	第一三共株式会社	経口用セファロスポリン製剤
FI20022007A0 (fi) *	2002-11-08	2002-11-08	Juvantia Pharma Ltd Oy	Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
AU2005272598B2 (en)	2004-08-12	2011-11-17	Helsinn Therapeutics (U.S.), Inc.	Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
GB201103397D0 (de)	2011-02-28	2011-04-13	Shire Movetis N V
US8568747B1 (en)	2012-10-05	2013-10-29	Silvergate Pharmaceuticals, Inc.	Enalapril compositions
US9463183B1 (en)	2015-10-30	2016-10-11	Silvergate Pharmaceuticals, Inc.	Lisinopril formulations
US9669008B1 (en)	2016-03-18	2017-06-06	Silvergate Pharmaceuticals, Inc.	Enalapril formulations
CN119700664B (zh) *	2025-02-28	2025-06-20	山东新时代药业有限公司	含有活性成分琥珀酸普芦卡必利的注射液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5374637A (en) *	1989-03-22	1994-12-20	Janssen Pharmaceutica N.V.	N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
GB9005014D0 (en) *	1990-03-06	1990-05-02	Janssen Pharmaceutica Nv	N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
JPH05163154A (ja) *	1991-12-13	1993-06-29	Kanebo Ltd	経口液剤
TW490465B (en) *	1994-11-24	2002-06-11	Janssen Pharmaceutica Nv	Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
KR20010080025A (ko)	1998-11-23	2001-08-22	디르크 반테	소화불량 치료용 의약의 제조를 위한 프루칼로프라이드의용도

2000
- 2000-04-17 TW TW089107124A patent/TW592709B/zh not_active IP Right Cessation
- 2000-04-17 JO JO200052A patent/JO2181B1/en active
- 2000-04-20 SI SI200030294T patent/SI1176982T1/xx unknown
- 2000-04-20 EA EA200101150A patent/EA003904B1/ru not_active IP Right Cessation
- 2000-04-20 HU HU0202324A patent/HU228924B1/hu unknown
- 2000-04-20 AT AT00931072T patent/ATE254929T1/de active
- 2000-04-20 EP EP00931072A patent/EP1176982B1/de not_active Expired - Lifetime
- 2000-04-20 CA CA002371178A patent/CA2371178C/en not_active Expired - Lifetime
- 2000-04-20 MX MXPA01010953A patent/MXPA01010953A/es active IP Right Grant
- 2000-04-20 JP JP2000615054A patent/JP4773619B2/ja not_active Expired - Lifetime
- 2000-04-20 CZ CZ20013735A patent/CZ294070B6/cs not_active IP Right Cessation
- 2000-04-20 UA UA2001107369A patent/UA68426C2/uk unknown
- 2000-04-20 TR TR2001/03121T patent/TR200103121T2/xx unknown
- 2000-04-20 ID IDW00200102322A patent/ID30397A/id unknown
- 2000-04-20 US US09/980,848 patent/US6413988B1/en not_active Expired - Lifetime
- 2000-04-20 CN CNB008065748A patent/CN1165345C/zh not_active Expired - Lifetime
- 2000-04-20 HR HR20010764A patent/HRP20010764B1/xx not_active IP Right Cessation
- 2000-04-20 DK DK00931072T patent/DK1176982T3/da active
- 2000-04-20 PT PT00931072T patent/PT1176982E/pt unknown
- 2000-04-20 HK HK02107621.0A patent/HK1045950B/zh not_active IP Right Cessation
- 2000-04-20 DE DE60006799T patent/DE60006799T2/de not_active Expired - Lifetime
- 2000-04-20 PL PL00352062A patent/PL195674B1/pl unknown
- 2000-04-20 EE EEP200100539A patent/EE05264B1/xx unknown
- 2000-04-20 ES ES00931072T patent/ES2211546T3/es not_active Expired - Lifetime
- 2000-04-20 WO PCT/EP2000/003739 patent/WO2000066170A1/en not_active Ceased
- 2000-04-20 KR KR1020017011858A patent/KR100669175B1/ko not_active Expired - Lifetime
- 2000-04-20 IL IL14615200A patent/IL146152A0/xx active IP Right Grant
- 2000-04-20 SK SK1519-2001A patent/SK284847B6/sk not_active IP Right Cessation
- 2000-04-20 BR BRPI0010150A patent/BRPI0010150B8/pt not_active IP Right Cessation
- 2000-04-20 AU AU49137/00A patent/AU770073B2/en not_active Expired
- 2000-04-20 NZ NZ515119A patent/NZ515119A/en not_active IP Right Cessation
- 2000-04-25 MY MYPI20001765A patent/MY119880A/en unknown
- 2000-04-28 AR ARP000102075A patent/AR023815A1/es active IP Right Grant
2001
- 2001-10-02 NO NO20014794A patent/NO331448B1/no not_active IP Right Cessation
- 2001-10-19 BG BG106031A patent/BG65061B1/bg unknown
- 2001-10-25 ZA ZA200108820A patent/ZA200108820B/en unknown
- 2001-10-25 IL IL146152A patent/IL146152A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT1176982E (pt)	2004-04-30
CZ20013735A3 (cs)	2002-02-13
AU770073B2 (en)	2004-02-12
ES2211546T3 (es)	2004-07-16
IL146152A0 (en)	2002-07-25
PL195674B1 (pl)	2007-10-31
EA003904B1 (ru)	2003-10-30
HK1045950B (zh)	2005-05-27
CA2371178A1 (en)	2000-11-09
HRP20010764B1 (hr)	2011-01-31
HU228924B1 (en)	2013-06-28
HRP20010764A2 (en)	2002-12-31
DE60006799T2 (de)	2004-09-23
EP1176982B1 (de)	2003-11-26
HUP0202324A3 (en)	2003-03-28
KR100669175B1 (ko)	2007-01-17
CZ294070B6 (cs)	2004-09-15
AU4913700A (en)	2000-11-17
TW592709B (en)	2004-06-21
EA200101150A1 (ru)	2002-04-25
IL146152A (en)	2006-12-31
ID30397A (id)	2001-11-29
EE05264B1 (et)	2010-02-15
HK1045950A1 (en)	2002-12-20
TR200103121T2 (tr)	2002-05-21
KR20020004972A (ko)	2002-01-16
ATE254929T1 (de)	2003-12-15
UA68426C2 (uk)	2004-08-16
CA2371178C (en)	2008-03-25
EP1176982A1 (de)	2002-02-06
NO20014794D0 (no)	2001-10-02
NO20014794L (no)	2001-10-02
EE200100539A (et)	2002-12-16
BR0010150A (pt)	2002-01-15
CN1348386A (zh)	2002-05-08
SI1176982T1 (en)	2004-04-30
JP4773619B2 (ja)	2011-09-14
MXPA01010953A (es)	2002-05-06
DK1176982T3 (da)	2004-03-29
BRPI0010150B8 (pt)	2021-05-25
CN1165345C (zh)	2004-09-08
SK15192001A3 (sk)	2002-03-05
HUP0202324A2 (hu)	2002-12-28
PL352062A1 (en)	2003-07-28
NZ515119A (en)	2003-05-30
DE60006799D1 (de)	2004-01-08
JO2181B1 (en)	2003-04-23
JP2002543161A (ja)	2002-12-17
BRPI0010150B1 (pt)	2015-06-23
US6413988B1 (en)	2002-07-02
BG106031A (en)	2002-05-31
WO2000066170A1 (en)	2000-11-09
AR023815A1 (es)	2002-09-04
SK284847B6 (sk)	2006-01-05
MY119880A (en)	2005-07-29
ZA200108820B (en)	2003-01-27
BG65061B1 (bg)	2007-01-31

Legal Events

Date	Code	Title	Description
2020-05-11	MK1K	Patent expired

Publication	Publication Date	Title
BE1009458A5 (fr)	1997-04-01	Compositions pharmaceutiques liquides orales contenant une imidazolecarbazolone.
CA2371178C (en)	2008-03-25	Prucalopride oral solution
KR20040005976A (ko)	2004-01-16	의약 액제
CZ20011286A3 (cs)	2001-09-12	Sertralinový perorální koncentrát
WO2000074685A1 (fr)	2000-12-14	Preparations orales d'etidronate disodique
KR20150127483A (ko)	2015-11-17	몬테루카스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 안정성이 개선된 액상 제제 및 이의 제조방법
JP2004292360A (ja)	2004-10-21	イソソルビド含有水性組成物
WO2012116976A1 (en)	2012-09-07	Prucalopride oral solution
JP4940523B2 (ja)	2012-05-30	ニザチジンの苦味をマスキングした液剤
US20060292189A1 (en)	2006-12-28	Ophthalmic solution with a flavoring agent as a dosing indicator and method for indicating dosage of an ophthalmic solution
JP5397026B2 (ja)	2014-01-22	内用液剤
PL237234B1 (pl)	2021-03-22	Ciekła doustna kompozycja farmaceutyczna chlorowodorku fenspirydu
JP2003055194A (ja)	2003-02-26	内服用液剤
KR20080016630A (ko)	2008-02-21	소아용 토피라메이트 제형